Literature DB >> 30458295

Regulatory effects of dermal papillary pluripotent stem cells on polarization of macrophages from M1 to M2 phenotype in vitro.

Meiying Li1, Jiayi Xu2, Xianglin Mei3, Guangfan Chi4, Lisha Li4, Yaolin Song4, Xia He4, Yulin Li5.   

Abstract

The M1:M2 macrophage ratio is important for spinal cord injury (SCI) repair. Bone marrow mesenchymal stem cells (BMSCs) can alter macrophage activation, promoting M1 to M2 macrophage conversion and SCI repair; however, clinical BMSC applications have limitations. Previously, we found DPCs to be superior to BMSCs in promoting tissue repair after SCI, which we hypothesized to be mediated by M1 to M2 macrophage conversion. We investigated the regulatory effect of DPCs on M1/M2 macrophage polarization. Dermal papilla cells (DPCs) were isolated from rat vibrissae and characterized. Bone marrow-derived macrophages (BMDMs) were isolated and identified based on specific marker expression, and stimulated to differentiate into M1 macrophages with GM-CSF, IFN-γ, and LPS. These cells were co-cultured with DPCs to evaluate the effect on macrophage differentiation. DPCs expressed dermal papillae-specific markers, including ALP and Sox2, had MSC-expression patterns like those of BMSCs, and were capable of multi-differentiation. BMDMs expressed ANAE and CD68. Three days after induction, differentiated cells exhibited morphology typical of M1-like macrophages and expressed the macrophage marker CD68 and the M1 macrophage markers iNOS, but lacked expression of the M2 macrophage marker CD206. Co-culture with DPCs resulted in a shift to anti-inflammatory M2-like macrophage differentiation, characterized by morphological changes typical of M2 macrophages, downregulation of the characteristic cytokine TNF-α and the proportion of iNOS+ cells, and upregulation of the characteristic cytokine IL-10 and the cell-surface marker CD206. The number of CD206-expressing M2 macrophages also increased. These findings demonstrate that DPCs reprogram macrophages to an anti-inflammatory M2 phenotype, which could improve adverse inflammatory microenvironments and promote tissue repair. Thus, DPCs may be an interesting alternative cell source and merit further investigation in applications for SCI therapy.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Dermal papilla cell; Macrophage; Mesenchymal stem cell; Polarization; Spinal cord injury

Mesh:

Substances:

Year:  2018        PMID: 30458295     DOI: 10.1016/j.trim.2018.11.003

Source DB:  PubMed          Journal:  Transpl Immunol        ISSN: 0966-3274            Impact factor:   1.708


  5 in total

1.  Schisandra Inhibit Bleomycin-Induced Idiopathic Pulmonary Fibrosis in Rats via Suppressing M2 Macrophage Polarization.

Authors:  Zhaojuan Guo; Siru Li; Nan Zhang; Qianjun Kang; Huaqiang Zhai
Journal:  Biomed Res Int       Date:  2020-08-20       Impact factor: 3.411

2.  Comparing the Efficacy and Safety of Cell Transplantation for Spinal Cord Injury: A Systematic Review and Bayesian Network Meta-Analysis.

Authors:  Xiongjie Xu; Zeyan Liang; Yike Lin; Jian Rao; Fabin Lin; Zhelun Yang; Rui Wang; Chunmei Chen
Journal:  Front Cell Neurosci       Date:  2022-04-04       Impact factor: 6.147

3.  Microporous structures on mineralized collagen mediate osteogenesis by modulating the osteo-immune response of macrophages.

Authors:  Jun Li; Xin Luo; Zhao-Yong Lv; Hui-Fen Qiang; Cai-Yao Hou; Kun Liu; Chun-Xiu Meng; Yu-Jue Zhang; Feng-Zhen Liu; Bin Zhang
Journal:  Front Bioeng Biotechnol       Date:  2022-08-29

4.  Effect of Nanostructured Scaffold on Human Adipose-Derived Stem Cells: Outcome of In Vitro Experiments.

Authors:  Marina Borgese; Ludovica Barone; Federica Rossi; Mario Raspanti; Roberto Papait; Luigi Valdatta; Giovanni Bernardini; Rosalba Gornati
Journal:  Nanomaterials (Basel)       Date:  2020-09-12       Impact factor: 5.076

Review 5.  Regulatory Role of Mesenchymal Stem Cells on Secondary Inflammation in Spinal Cord Injury.

Authors:  Qi-Ming Pang; Si-Yu Chen; Sheng-Ping Fu; Hui Zhou; Qian Zhang; Jun Ao; Xiao-Ping Luo; Tao Zhang
Journal:  J Inflamm Res       Date:  2022-01-26
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.